Barclays analyst Peter Lawson lowered the firm’s price target on Arcus Biosciences (RCUS) to $14 from $29 and keeps an Overweight rating on the shares. The firm “derisked” the company’s model.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS: